These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 11976073)
61. Novel approaches to lipid lowering: what is on the horizon? Brown WV Am J Cardiol; 2001 Mar; 87(5A):23B-27B. PubMed ID: 11256846 [TBL] [Abstract][Full Text] [Related]
62. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Hirsch M; O'donnell J; Olsson A Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052 [TBL] [Abstract][Full Text] [Related]
63. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Chapman MJ; McTaggart F Atheroscler Suppl; 2002 Apr; 2(4):33-6; discussion 36-7. PubMed ID: 11976075 [TBL] [Abstract][Full Text] [Related]
64. Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. Soran H; Adam S; Durrington PN Eur J Prev Cardiol; 2017 Jan; 24(1):76-83. PubMed ID: 27609614 [TBL] [Abstract][Full Text] [Related]
65. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
66. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Jones P; Kafonek S; Laurora I; Hunninghake D Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454 [TBL] [Abstract][Full Text] [Related]
67. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
68. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777 [TBL] [Abstract][Full Text] [Related]
69. Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Chong PH; Varner D Pharmacotherapy; 2005 Feb; 25(2):270-8. PubMed ID: 15767241 [TBL] [Abstract][Full Text] [Related]
70. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Kim HS; Wu Y; Lin SJ; Deerochanawong C; Zambahari R; Zhao L; Zhang Q; Yan P Curr Med Res Opin; 2008 Jul; 24(7):1951-63. PubMed ID: 18547466 [TBL] [Abstract][Full Text] [Related]
71. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336 [TBL] [Abstract][Full Text] [Related]
72. Management of dyslipidemia in the high-risk patient. Stein EA Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415 [TBL] [Abstract][Full Text] [Related]
73. A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. Alder M; Bavishi A; Zumpf K; Peterson J; Stone NJ Am J Med; 2020 Nov; 133(11):1322-1327. PubMed ID: 32416177 [TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E; Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428 [TBL] [Abstract][Full Text] [Related]
75. Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Khush KK; Waters D Cleve Clin J Med; 2004 Aug; 71(8):609-16. PubMed ID: 15449756 [TBL] [Abstract][Full Text] [Related]
77. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E; Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418 [TBL] [Abstract][Full Text] [Related]
78. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Tran YB; Frial T; Miller PS Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788 [TBL] [Abstract][Full Text] [Related]
79. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? Jacobson TA Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219 [TBL] [Abstract][Full Text] [Related]